Roche deal fails to Repare the licensing scene

Roche’s move for Repare Therapeutics’ cancer candidate camonsertib earlier this month was quickly eclipsed by Bristol Myers Squibb’s $4.1bn purchase of Turning Point and the Asco meeting. However, the $125m signing fee that Repare received was the fourth-largest up-front payment that 2022 has seen so far, according to an analysis by Evaluate Vantage.